These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25038505)

  • 1. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
    Danielsen SA; Lind GE; Kolberg M; Høland M; Bjerkehagen B; Sundby Hall K; van den Berg E; Mertens F; Smeland S; Picci P; Lothe RA
    Neuro Oncol; 2015 Jan; 17(1):63-9. PubMed ID: 25038505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
    Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
    Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
    Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
    J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Nguyen R; Jett K; Harris GJ; Cai W; Friedman JM; Mautner VF
    J Neurooncol; 2014 Jan; 116(2):307-13. PubMed ID: 24166582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis.
    Koga T; Iwasaki H; Ishiguro M; Matsuzaki A; Kikuchi M
    J Pathol; 2002 May; 197(1):98-107. PubMed ID: 12081210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours.
    Harder A; Rosche M; Reuss DE; Holtkamp N; Uhlmann K; Friedrich R; Mautner VF; von Deimling A
    Eur J Cancer; 2004 Dec; 40(18):2820-8. PubMed ID: 15571966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
    Lim Z; Gu TY; Tai BC; Puhaindran ME
    World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
    Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.
    Park SJ; Sawitzki B; Kluwe L; Mautner VF; Holtkamp N; Kurtz A
    BMC Med; 2013 Apr; 11():109. PubMed ID: 23618374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.